BMS-265246

Overview

BMS-265246 is a potent and selective cyclin-dependent kinase CDK1 and CDK2 inhibitor, with IC 50 values of 6 and 9 nM, respectively. BMS-265246 inhibits CHI3L1 (chitinase 3-like-1) stimulation of ACE2 (angiotensin converting enzyme 2) and SPP (viral spike protein priming proteases). BMS-265246 can be used for ovarian cancer and COVID-19 research.

Application

Products | Products > Disease Areas > Infection | Products > Disease Areas > Cardiovascular Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Leukemia/Lymphoma/Myeloma | Products > Disease Areas > Blood Disease | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Hypertension | Products > Disease Areas > Cancer | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Infection | Products > Research Areas > Cardiovascular Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > CDK | Products > Signaling Pathways > Angiotensin-converting Enzyme (ACE)

Product Information

• Catalog No.: HY-15275
• CAS No.: 582315-72-8
• Molecular Formula: C18H17F2N3O2
• Molecular Weight: 345.34
• Purity: 99.59%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
• Solubility: 2.08 mg/mL (6.02 mM); Suspended solution; Need ultrasonic
• Availability: In-stock

Source

Original product source